63 related articles for article (PubMed ID: 15887124)
1. Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer.
Worthley DL; Walsh MD; Barker M; Ruszkiewicz A; Bennett G; Phillips K; Suthers G
Gastroenterology; 2005 May; 128(5):1431-6. PubMed ID: 15887124
[TBL] [Abstract][Full Text] [Related]
2. Co-Occurrence of Familial Non-Medullary Thyroid Cancer (FNMTC) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Associated Tumors-A Cohort Study.
Aswath K; Welch J; Gubbi S; Veeraraghavan P; Avadhanula S; Gara SK; Dikoglu E; Merino M; Raffeld M; Xi L; Kebebew E; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2021; 12():653401. PubMed ID: 34326811
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2.
Narayanan L; Fritzell JA; Baker SM; Liskay RM; Glazer PM
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3122-7. PubMed ID: 9096356
[TBL] [Abstract][Full Text] [Related]
4. Altered spectra of hypermutation in antibodies from mice deficient for the DNA mismatch repair protein PMS2.
Winter DB; Phung QH; Umar A; Baker SM; Tarone RE; Tanaka K; Liskay RM; Kunkel TA; Bohr VA; Gearhart PJ
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6953-8. PubMed ID: 9618520
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma in a man with hereditary nonpolyposis colon cancer.
Lenz DL; Harpster LE
Rev Urol; 2003; 5(1):49-53. PubMed ID: 16985618
[TBL] [Abstract][Full Text] [Related]
6. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer.
Nicolaides NC; Papadopoulos N; Liu B; Wei YF; Carter KC; Ruben SM; Rosen CA; Haseltine WA; Fleischmann RD; Fraser CM
Nature; 1994 Sep; 371(6492):75-80. PubMed ID: 8072530
[TBL] [Abstract][Full Text] [Related]
7. Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes.
Vaughn CP; Robles J; Swensen JJ; Miller CE; Lyon E; Mao R; Bayrak-Toydemir P; Samowitz WS
Hum Mutat; 2010 May; 31(5):588-93. PubMed ID: 20205264
[TBL] [Abstract][Full Text] [Related]
8. Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants.
Borràs E; Pineda M; Cadiñanos J; Del Valle J; Brieger A; Hinrichsen I; Cabanillas R; Navarro M; Brunet J; Sanjuan X; Musulen E; van der Klift H; Lázaro C; Plotz G; Blanco I; Capellá G
J Med Genet; 2013 Aug; 50(8):552-63. PubMed ID: 23709753
[TBL] [Abstract][Full Text] [Related]
9. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
[TBL] [Abstract][Full Text] [Related]
10. PMS2 gene mutational analysis: direct cDNA sequencing to circumvent pseudogene interference.
Wimmer K; Wernstedt A
Methods Mol Biol; 2014; 1167():289-302. PubMed ID: 24823786
[TBL] [Abstract][Full Text] [Related]
11. The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer.
Ketabi Z; Gerdes AM; Mosgaard B; Ladelund S; Bernstein I
Gynecol Oncol; 2014 Jun; 133(3):526-30. PubMed ID: 24631699
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
Castéra L; Krieger S; Rousselin A; Legros A; Baumann JJ; Bruet O; Brault B; Fouillet R; Goardon N; Letac O; Baert-Desurmont S; Tinat J; Bera O; Dugast C; Berthet P; Polycarpe F; Layet V; Hardouin A; Frébourg T; Vaur D
Eur J Hum Genet; 2014 Nov; 22(11):1305-13. PubMed ID: 24549055
[TBL] [Abstract][Full Text] [Related]
13. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Bonadona V; Bonaïti B; Olschwang S; Grandjouan S; Huiart L; Longy M; Guimbaud R; Buecher B; Bignon YJ; Caron O; Colas C; Noguès C; Lejeune-Dumoulin S; Olivier-Faivre L; Polycarpe-Osaer F; Nguyen TD; Desseigne F; Saurin JC; Berthet P; Leroux D; Duffour J; Manouvrier S; Frébourg T; Sobol H; Lasset C; Bonaïti-Pellié C;
JAMA; 2011 Jun; 305(22):2304-10. PubMed ID: 21642682
[TBL] [Abstract][Full Text] [Related]
14.
Poaty H; Bouya LB; Lumaka A; Mongo-Onkouo A; Gassaye D
Glob Med Genet; 2023 Jan; 10(1):1-5. PubMed ID: 36644715
[No Abstract] [Full Text] [Related]
15. Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy.
Deycmar S; Gomes B; Charo J; Ceppi M; Cline JM
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593067
[TBL] [Abstract][Full Text] [Related]
16. Detection of clinically relevant copy-number variants by exome sequencing in a large cohort of genetic disorders.
Pfundt R; Del Rosario M; Vissers LELM; Kwint MP; Janssen IM; de Leeuw N; Yntema HG; Nelen MR; Lugtenberg D; Kamsteeg EJ; Wieskamp N; Stegmann APA; Stevens SJC; Rodenburg RJT; Simons A; Mensenkamp AR; Rinne T; Gilissen C; Scheffer H; Veltman JA; Hehir-Kwa JY
Genet Med; 2017 Jun; 19(6):667-675. PubMed ID: 28574513
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.
Heinen CD
DNA Repair (Amst); 2016 Feb; 38():127-134. PubMed ID: 26710976
[TBL] [Abstract][Full Text] [Related]
18. PMS2 monoallelic mutation carriers: the known unknown.
Goodenberger ML; Thomas BC; Riegert-Johnson D; Boland CR; Plon SE; Clendenning M; Win AK; Senter L; Lipkin SM; Stadler ZK; Macrae FA; Lynch HT; Weitzel JN; de la Chapelle A; Syngal S; Lynch P; Parry S; Jenkins MA; Gallinger S; Holter S; Aronson M; Newcomb PA; Burnett T; Le Marchand L; Pichurin P; Hampel H; Terdiman JP; Lu KH; Thibodeau S; Lindor NM
Genet Med; 2016 Jan; 18(1):13-9. PubMed ID: 25856668
[TBL] [Abstract][Full Text] [Related]
19. Milestones of Lynch syndrome: 1895-2015.
Lynch HT; Snyder CL; Shaw TG; Heinen CD; Hitchins MP
Nat Rev Cancer; 2015 Mar; 15(3):181-94. PubMed ID: 25673086
[TBL] [Abstract][Full Text] [Related]
20. Predictive genetic testing of a bone marrow recipient-ethical issues involving unexpected results, gender issues, test accuracy, and implications for the donor.
Sexton A; Rawlings L; Jenkins M; Winship I
J Genet Couns; 2014 Feb; 23(1):33-7. PubMed ID: 23990319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
